Navigation Links
SGX Pharmaceuticals Announces First Quarter Financial Results and Gives Pipeline Update
Date:5/13/2008

$0.21 $(0.03) $0.18 $(0.01) $(0.06) $(0.07)

Diluted net income

(loss) per common

share: $0.21 $(0.03) $0.18 $(0.01) $(0.06) $(0.07)

Research and

development

expenses $11,055 $294 $11,349 $9,517 $501 $10,018

General and

administrative

expenses $1,789 $332 $2,121 $1,745 $488 $2,233

SGX PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands)

(unaudited)

March 31, December 31,

2008 2007

Assets

Cash, cash equivalents and short-term

investments $30,867 $38,990

Accounts receivable 1,645 2,706

Other current assets 1,847 1,187

Property and equipment, net 3,842 3,889

Other assets 4,285 4,284

Total assets $42,486 $51,056

Liabilities and stockholder's equity

Current liabilities $12,190 $24,991

Deferred revenue, long-term 904 1,042

Other liabilities, net of current portion - -

Stockholder's equity 29,392 25,023

Total liabilities and stockholder's equity $42,486 $51,056

1) In addition to disclosing financial results calculated in accordance

with generally accepted accounting principles (GAAP), this table

contains non-GAAP financial measures that
'/>"/>

SOURCE SGX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... VA (PRWEB) January 15, 2014 Two ... have continued their sponsorship of an annual competition for ... in, and access to, innovative STEM study. The competition ... TEAMS: Tests of Engineering Aptitude, Mathematics, and Sciences ...
(Date:1/15/2014)... DTS Language Services, Inc . is pleased to announce ... organizations who need document translations. Clients will now have ... in advance with a selection of nearly 50 life science ... critical factor in clinical and scientific fields, and decrease the ...
(Date:1/15/2014)... 15, 2014 Freeslate, Inc ., ... announced that Lupin Limited, one of India’s top five ... Protégé PharmD System for high throughput solid form ... focused on a wide range of quality, affordable generic ...
(Date:1/15/2014)... TaiGen Biotechnology Company, Limited ("TaiGen") today announced that they ... Russian pharmaceutical company, to develop and commercialize nemonoxacin (Taigexyn ... , Turkey and other members ... antibiotic for the treatment of bacterial infections including those ...
Breaking Biology Technology:Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5DTS Improves Efficiency for Life Science Document Translations 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4
... PATENT FOR APPARATUS AND,METHOD FOR RESPIRATORY TRACT THERAPY, ... leader in High Flow Oxygen Therapy products, announced ... an apparatus used in the,delivery tube technology for ... industry, the U.S. Patent No. 7,314,046,B2 has been ...
... JOSE, Calif., Jan. 22 Clinimetrics today announced,a ... a leading contract research,organization (CRO) with a particular ... stage pharmaceutical and medical device companies., (Logo: ... CEO of Clinimetrics, commented, "During the past,two decades, ...
... A free white paper for clinical,laboratory managers ... Spiral Biotech, Inc. at, http://www.aicompanies.com/anoxomat ., As ... faced with the ongoing challenge of quickly determining ... pathogens. As a result, clinical laboratories,face growing pressure ...
Cached Biology Technology:Vapotherm(R) Announces Validation of U.S. Patent 2Free White Paper Available for Clinical Laboratory Managers: 'Effectively Isolating Anaerobic Bacteria' 2
(Date:4/17/2014)... professor Rajendra Singh Thursday as a "Champion of ... solar deployment in the residential, commercial and industrial ... of Electrical and Computer Engineering and director of ... local hero leading the charge across the country ... power and driving policy changes at the local ...
(Date:4/17/2014)... and fragmentation of forests in the Amazon help ... contributing to rapid and widespread forest loss during ... The findings show that forests in the Amazon ... coupled with forest fires lead to large-scale loss ... Balch, assistant professor of geography, Penn State. , ...
(Date:4/17/2014)... IPCC meeting painted a stark warning on the possible ... a greenhouse effect 32 times that of carbon dioxide. ... humic substances act as fully regenerable electron acceptors which ... in wetlands instead of being released to the atmosphere. ... disrupted it may enter into a vicious cycle to ...
Breaking Biology News(10 mins):White House honors Clemson professor as 'Champion of Change' for solar deployment 2Drought and fire in the Amazon lead to sharp increases in forest tree mortality 2Drought and fire in the Amazon lead to sharp increases in forest tree mortality 3Methane climate change risk suggested by proof of redox cycling of humic substances 2
... Dec. 2013): Ulsan National Institute of Science and Technology ... boron/nitrogen co-doped graphene nanoplatelets, which led to the fabrication ... nature. This opens up opportunities for practical use in ... Science and Technology (UNIST) research team led by Prof. ...
... during storms and release stored water during droughts, according ... in Panama. Their results lend credence to a controversial ... the center of a debate about how to minimize ... , During nearly 450 tropical storms, a team of ...
... recent study led by scientists from the National University of ... Spinal Muscular Atrophy (SMA), a devastating disease that is the ... young adults. As there is currently no known cure for ... fight against SMA. SMA is caused by deficiencies ...
Cached Biology News:UNIST research team opens graphene band-gap 2Tropical forests mitigate extreme weather events 2Study led by NUS scientists provides new insights into cause of human neurodegenerative disease 2Study led by NUS scientists provides new insights into cause of human neurodegenerative disease 3
... and efficient method for purification of DNA fragments ... fragments selectively absorbed in the spin column after ... room temperature for PCR product with equal volume ... DNA can be purified with a single prep ...
BlotGel application pool -see Blotters (Semi-Dry) for more info...
lid holder -see Blotters (Semi-Dry) for more info...
When added to either StemSep CD4+ or CD8+ T Cell Enrichment cocktails, human CD45RA TAC is designed to deplete human CD45RA from samples to isolate memory CD4+ or CD8+ T cells....
Biology Products: